公司比較

簡介

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating disease by silencing the genes that cause it. Its ATTR franchise has established RNAi as a validated drug modality, and its deep pipeline across cardiometabolic, CNS, and infectious diseases promises to expand the platform's reach.

營收

$2.4B

新聞缺口信號

此股票代碼沒有新聞缺口數據。

機構信號

此代號沒有13F信號記錄。

級聯模式

未出現在任何追蹤的級聯模式中。

關鍵關係

簡介

NVIDIA is the dominant designer of graphics processing units and AI accelerator chips. Its data-center GPU monopoly powers the generative-AI revolution, with the H100 and successor Blackwell GPUs serving as the de-facto standard for training and running large language models.

營收

$130.5B

新聞缺口信號

機構信號

級聯模式

關鍵關係